Well after all the earlier promises, now slightly overdue and the SMA chart starting to indicate a reversal of fortune I think you might be wise to buy some. Or if you hold some, top up as I've been doing lately.

For those not familiar with this stock check on previous news over the last year or so re 'promises'.

In shares today - watch the cash position as they are burning it.

INTERIM RESULTS FOR SIX MONTHS ENDED 30 JUNE 2013

RNS


RNS Number : 1858P

Plethora Solutions Holdings PLC

30 September 2013












PLETHORA SOLUTIONS HOLDINGS PLC

("Plethora" or the "Company")

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2013



Plethora is pleased to announce its interim results for the six months ended 30 June 2013.



Highlights



· Refocusing of business solely on PSD502



· Successful placing raising £2.1 million together with debt restructuring



· Now responsible for regulatory and commercial development of PSD502 globally



· Strengthening of Plethora board



· A CHMP positive opinion in relation to PSD502 approval for European Union in September 2013



Ronald Openshaw, CEO of Plethora said:



"2013 has so far been an exceptional year for Plethora, We have focussed the Group's full effort on PSD502; expanded our geographic interest in the product; commenced work on the filing with the FDA in the United States and achieved a milestone in the European regulatory process. Our efforts are to ensure that PSD502 is brought to market to ease the distress of so many couples".





- Ends -

Moving up nice, on a poor markets day.

probably reverse a bit more as from 20th September it is approximately 60 days after a CHMP recommendation to final decision - then imo watch it really fly on receipt of that

Up 11%

UPDATE - Plethora Solutions' cash call supported by institutions
By Giles Gwinnett October 15 2013, 4:51pm It will also provide working capital to continue the group's partnering activities for the commercial launch of PSD502, it saidIt will also provide working capital to continue the group's partnering activities for the commercial launch of PSD502, it said

Plethora Solutions (LON:PLE) is to raise £4.4mln to advance its treatment for premature ejaculation.



The company is issuing 49mln shares that will be purchased at 49p a pop, primarily by institutional investors, including funds associated with Jim Mellon, Plethora’s non-executive chairman.

Shares in Plethora closed at 11.13p the day before the share issue was announced.

"The proceeds of this financing will be used to complete the last steps of regulatory approval in the Europe, but importantly will fund the filing and prosecution of a New Drug Application (NDA) with the US Food and Drug Administration (FDA),” the company said in a statement.

It will also provide working capital to continue the group's partnering activities for the commercial launch of PSD502, it said.

The company disclosed that 22.33mln shares will be available through subscription, raising £2.0mln; of this, £1.8mln will come from entities associated with Jim Mellon. A further £100,000 will be subscribed to by other directors, including chief executive Ronald Openshaw, chief scientific officer Professor Michael Wyllie and non-executive director Dr Greg Bailey.

Institutional investors will sign up for 26.7mln shares to raise £2.4mln.

"Over the last few months Plethora has delivered the agreement to control global development and commercialisation of PSD502 and the positive opinion from the CHMP. Based on the positive effect on the company's valuation we have secured the resources to execute our near term strategy of seeing approval of PSD502 and generating a financial return to shareholders," Openshaw said.

This is looking good for the next fw months..potential for the share of 2014! (imho, dyor!)

another very good day - likely to end the week circa 20p
gl

onwards & upwards :-0

Hopefully see this pick up again from November onwards. Could be truly amazing.

Up 13.5%

Up 22%

Closed up just under 26%

hope you are in dc - another fantastic day
atb

:-))

looking strong before eu approval rubber stamping rns now the merlin overhang cleared

Directors dealings - (Buys) -

Chairman J Mellon 20,000,000 £1.8 million 1Nov

ce and cfo R Openshaw 333,500 £30,015 1 Nov


Dr. GH Bailey 55,600 £5,004 1 Nov


Dr. MG Wyllie 333,500 £30,015 1 Nov



All Dealings at 9p

FULLY APPROVED RNS CONFIRMS - GOING TO BE A MAD RUSH THIS MORNING................. kerrrrrrrrrrrrrrrchinnnnnnnnnnngggggggggggggggggggggggg


RNS


RNS Number : 3479T

Plethora Solutions Holdings PLC

19 November 2013








19 November 2013



Plethora Solutions Holdings PLC

("Plethora" or the "Company")

European Commission Approval





Plethora Solutions Holdings plc (AIM: PLE) announces that the European Commission has granted marketing authorisation for the Company's treatment for primary premature ejaculation in adult men under the name 'Prilocaine Lidocaine Plethora'. This product is also referred to by the Company under its development code PSD502.



PSD502 was developed by the Company for the treatment of primary premature ejaculation and demonstrated a highly statistically and clinically significant improvement in the primary measures of intravaginal ejaculation latency time (IELT), control and satisfaction in two pivotal, double-blind, placebo controlled phase III studies. In these studies, the product was shown in over 23,000 exposures to be well accepted by patients.



Premature ejaculation is probably the most prevalent sexual dysfunction in men. The condition has been characterised by the International Society of Sexual Medicine (ISSM) as being "a male sexual dysfunction" characterised by: ejaculation that always or nearly always occurs prior to or within about one minute of vaginal penetration; the inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences such as distress, bother, frustration and/or the avoidance of sexual intimacy.



The Company estimates that there are in excess of 150 million men aged between 20-69 years old in the European Union. With an estimated incidence of PE of 20-30% of men, this implies that the potential population of men in the EU with the disorder is approximately 30-45 million.



Jim Mellon Chairman of Plethora said:



"Plethora was founded in 2004 to develop PSD502; in 2011 the Company regained control of the European approval process and PSD502 has now been approved by the European Commission. In August this year Plethora regained global control of PSD502 and work is well underway to file with the FDA in early New Year. We are delighted by today's news that represents an important step in the successful commercialisation of the product. Premature ejaculation can cause serious distress for those men who suffer from the condition and we hope that PSD502 will help them and their partners"

UPDATE - Plethora Solutions granted EU marketing approval
By Jamie Nimmo November 19 2013, 12:40pm The company estimates 30-45mln men between 20 and 69 years old in the EU suffer from premature ejaculationThe company estimates 30-45mln men between 20 and 69 years old in the EU suffer from premature ejaculation

--ADDS SHARE PRICE, BROKER COMMENTS--

Plethora Solutions’ (LON:PLE) treatment for premature ejaculation has been granted marketing authorisation by the EU’s executive body, the European Commission (EC).

In September, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) advised the EC to approve PSD502, which will go under the name ‘Prilocaine Lidocaine Plethora’.

The company estimates 30-45mln men between 20 and 69 years old in the EU suffer from the sexual dysfunction.

Chairman Jim Mellon said: “Plethora was founded in 2004 to develop PSD502; in 2011 the company regained control of the European approval process and PSD502 has now been approved by the European Commission.

“In August this year Plethora regained global control of PSD502 and work is well underway to file with the FDA [US Food and Drug Administration] in early New Year.”

He continued: “We are delighted by today's news that represents an important step in the successful commercialisation of the product.

“Premature ejaculation can cause serious distress for those men who suffer from the condition and we hope that PSD502 will help them and their partners.”

Broker Daniel Stewart estimates that the group could receive approval to the US market in the second half of 2015.

It lifts its target price from 15.7p to 18.9p to reflect the lower risk associated with investing in the company now it has secured the EC approval.

“Finally, we reiterate our belief that PSD502 has the potential to go mass-market,” said the broker, which believes such an outcome would transform Plethora into a “large business”.

Plethora’s shares spiked in early deals but settled 3% higher at 17.1p. They have risen over 1,000% in the past six months.